Homozygous Familial Hypercholesterolemia (HoFH) Latest Advances
Find the Latest Research About Homozygous Familial Hypercholesterolemia (HoFH)
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1990 publications
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.
Journal: Circulation research
Published: June 04, 2026
Translating Lipoprotein Genetics Into New Therapies.
Journal: Circulation research
Published: June 04, 2026
Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.
Journal: Expert opinion on therapeutic targets
Published: May 07, 2026
Homozygous familial hypercholesterolemia: Will new LDL-C-lowering drugs replace lipoprotein apheresis?
Journal: European journal of preventive cardiology
Published: April 28, 2026
50 years of apheresis for homozygous familial hypercholesterolemia.
Journal: Nature cardiovascular research
Published: April 17, 2026
Management of autosomal recessive hypercholesterolemia in a patient with an LDLRAP1 mutation.
Journal: Journal of clinical lipidology
Published: April 02, 2026
An Improved Prognosis in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in LDL-Lowering Therapy.
Journal: Journal of atherosclerosis and thrombosis
Published: March 29, 2026
Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia.
Journal: Journal of atherosclerosis and thrombosis
Published: March 29, 2026
The safety and efficacy of adeno-associated virus-mediated LDLR transfection in homozygous familial hypercholesterolemia
Journal: Zhonghua xin xue guan bing za zhi
Published: March 22, 2026
Homozygous familial hypercholesterolemia (HoFH) in Canada.
Journal: Atherosclerosis
Published: March 20, 2026
Last Updated: 06/30/2026